Geisinger Medical Laboratories Test Catalog
NRAS MUTATION ANALYSIS, PCR |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB2773 Geisinger Epic ID: 45933 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Formalin-fixed, paraffin-embedded tissue (FFPE) | |
Specimen required: |
Two (2) 10 micron sections in 50 mL tube (preferred), four (4) 10 micron FFPE unstained slides with H&E, or paraffin block. | |
Special notes: |
For requests from non-Geisinger sites, please send: Five (5) 10 micron FFPE sections (scrolls)- preferred specimen, H&E slide, source of specimen, and tumor assessment (<10% or >10%). Alternatively, send FFPE block. Isolated/extracted nucleic acids are acceptable only from CLIA-certified laboratories or a laboratory meeting equivalent requirements as determined by CAP and/or CMS. | |
SPECIMEN PROCESSING |
||
Transport temperature: |
Room temperature (18-25°C). | |
Specimen stability: |
Indefinitely. | |
Rejection criteria: |
Blocks containing no tumor (evaluted by pathologist) will be rejected. FFPE tissues that have been decalcified. Insufficient DNA. | |
TEST DETAILS |
||
Reference interval: |
Negative for mutation(s) tested. | |
CPT code(s): |
81311 | |
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Identification of NRAS mutations in codons 12, 13, 59, 61, 117, and 146. | |
Methodology: |
Real-time Polymerase Chain Reaction (PCR) |
|
Synonyms: |
NRAS, N-ras, NRAS gene, N-RAS protein
|
|
Clinical significance: |
Testing for NRAS mutations is used to predict response to anti-EGFR and MAPK pathway therapies in a variety of malignancies (e.g. colorectal and lung cancer). | |
Doctoral Director(s:) |
Yi Ding MD, PhD | |
Review Date: | 12/20/2022 |